(CercleFinance.com) – AstraZeneca indicates that its Imfinzi-Imjudo combination is recommended by the CHMP for marketing authorization in the European Union, in the first-line treatment of adult patients with advanced liver cancer or unresectable.
This combination is also recommended in combination with platinum-based chemotherapy for the treatment of adult patients with stage IV (metastatic) non-small cell lung cancer (NSCLC).
The European Medicines Agency’s CHMP bases these positive opinions on the results of the phase III HIMALAYA trial, published in the New England Journal of Medicine Evidence, and on those of the phase III POSEIDON trial, published in the Journal of Clinical Oncology.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
